Evropska unija - slovenščina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Evropska unija - slovenščina - EMA (European Medicines Agency)

betapharm arzneimittel gmbh - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine betapharm je indiciran za zdravljenje odraslih bolnikih, ki niso primerni za haematopoietic stem cell presaditev (hsct) z:vmesne-2 in visokim tveganjem myelodysplastic sindromov (mds) je v skladu z mednarodnim prognostic sistem točkovanja (ipss),kronične myelomonocytic levkemijo (cmml) z 10 % na 29 % mozga eksplozije brez myeloproliferative motnje,akutno mieloično levkemijo (aml) z 20 % do 30 % blastov in multi-rodbine displazija, po ocenah svetovne zdravstvene organizacije (who) razvrstitev,aml s > 30 % mozgu eksplozije glede na razvrstitev, ki.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine soglasju je indicirano za zdravljenje odraslih bolnikih, ki niso primerni za haematopoietic stem cell presaditev (hsct) z:- intermediate-2 in visokim tveganjem myelodysplastic sindromov (mds) je v skladu z mednarodnim prognostic sistem točkovanja (ipss),- kronično myelomonocytic levkemijo (cmml) z 10-29 % mozga eksplozije brez myeloproliferative motnje,- akutno mieloično levkemijo (aml) z 20-30 % blastov in multi-rodbine displazija, po ocenah svetovne zdravstvene organizacije (who), in razvrščanje,- aml s >30% mozgu eksplozije glede na razvrstitev, ki.

Evropska unija - slovenščina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - leukemija, myeloid, akutna - antineoplastična sredstva - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Evropska unija - slovenščina - EMA (European Medicines Agency)

neovii biotech gmbh - catumaxomab - ascites; cancer - drugi antineoplastiki - removab je indiciran za intraperitonealno zdravljenje malignih ascitesov pri bolnikih s pozitivnimi karcinomom epcam, pri katerih standardna terapija ni na voljo ali ni več izvedljiva.

Evropska unija - slovenščina - EMA (European Medicines Agency)

krka, d.d., novo mesto - emtricitabine, tenofovir disoproxil succinate - okužbe z virusom hiv - antivirusi za sistemsko uporabo - emtricitabin / tenofovirdizoproksil krka d. je indiciran pri protiretrovirusnem kombiniranem zdravljenju za zdravljenje odraslih, okuženih s hiv-1. emtricitabin / tenofovirdizoproksil krka d. je tudi navedeno, za zdravljenje okužbe z virusom hiv-1 okuženih mladostniki, z nrti odpornost ali toxicities nasprotuje uporabi prvo vrstico agenti, starih od 12 < 18 let.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

hospira uk ltd. - vankomicin - prašek za koncentrat za raztopino za infundiranje - vankomicin 500 mg / 1 viala - vankomicin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

hospira uk ltd. - vankomicin - prašek za koncentrat za raztopino za infundiranje - vankomicin 1000 mg / 1 viala - vankomicin

Evropska unija - slovenščina - EMA (European Medicines Agency)

elanco gmbh - pegbovigrastim - colony stimulating factors, immunostimulants, zdravila z delovanjem na novotvorbe agenti - cattle (cows and heifers); cattle - kot pomoč v programu za črede zmanjšati tveganje za klinični mastitis v perifernih mlečnih kravah in telicah v 30 dneh po telitvi.